Pathway health corporate presentation (june 2021)

1. page 1
Investor Presentation
October 2020
CORPORATE PRESENTATION
June 2021

2. page 2
DISCLAIMER
Certain statements contained in this presentation constitute forward-looking statements. The words “anticipate”,
“continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions typically are
used to identify forward-looking statements. By their nature, forward-looking statements and information involve
known and unknown opportunities, costs, risks and uncertainties that may cause actual results to differ materially
from those anticipated. Except for statements of historical fact, certain information contained herein constitutes
forward-looking statements which include management’s assessment of future plans and operations and are based
on current internal expectations, estimates, projections, assumptions and beliefs, which may prove to be incorrect.
The use of forward-looking statements reflects our current views, expectations, estimates and/or projections with
respect to our performance, business and future events, and in this presentation includes statements relating to,
among others: expectations regarding our business; expectations relating to our business goals, objectives and
schedules; expectations regarding the cannabinoid based therapy industry, including Canada’s position therein;
expectations regarding the acceptance of cannabinoid based therapies in the medical community; expectations
regarding our clinical development plans; expectations regarding development of new intellectual property, including
from cannabinoid product combinations; expectations related to the anticipated closing of the subscription receipt
offering and reverse take-over with a Capital Pool Company; the terms and conditions of the subscription receipt
offering; and the use of proceeds from the subscription receipt offering. Forward-looking statements are prepared by
management and based on the then-current expectations, forecasts and assumptions about the business and the
industry and markets in which we operate, including, among others: that there will be no unforeseen delays,
disruptions, market forces, regulations or laws that will prevent us from operating our business; that we will be able
to obtain the capital we require; that the subscription receipt offering has closed; that the escrow release conditions
in respect of the subscription receipt offering have been fulfilled; and that the reverse take-over has been completed.
Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and
assumptions which are difficult to predict, including, without limitation: that we may experience unforeseen delays,
financing difficulties or costs that will impact our projects, operations, financial performance or liquidity; that we will
not be able to advance our business plan or continue operations; that we will not be able to obtain insurance for our
operations; that we will not be able to protect our intellectual property; that we will not be able to develop and
commercialize, or obtain regulatory approvals to commercialize, products derived from our intellectual property; that
we will not be able to recruit physicians for our clinics; that regulatory approvals of products developed from our
intellectual property may result in significant delays; that development of cannabinoid based therapies may expose
us to liability claims in excess of our insurance coverage; and those risks relating to the occurrence of national
disasters, hostilities, acts of war or terrorism, our reputation, our key personnel, competition, employee relations,
changes in the cannabinoid based therapy market generally, potential downturns in economic conditions, pandemics,
foreign exchange fluctuations, fluctuations in the currency markets, inflationary pressures, changes in interest rates,
changes in regulatory requirements which may alter or prohibit investment in our business, or changes in national
and local government legislation, taxation, controls, regulations and political or economic developments in Canada or
any other country in which we operate or intend to operate.
These risks, as well as others, could cause actual results and events to differ materially from those anticipated in
such forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking
statements and information, which are qualified in their entirety by this cautionary statement. These statements
speak only as of the date of this presentation and we do not undertake any obligations to update such forward-
looking statements, except as required by applicable securities law.
To the extent any forward-looking information in this presentation constitutes “future-oriented financial
information” or “financial outlooks” within the meaning of applicable Canadian securities laws, such information is
being provided to demonstrate the potential benefits of the company’s business plans and strategies, and the reader
is cautioned that this information may not be appropriate for any other purpose and the reader should not place
undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial
information and financial outlooks, as with forward-looking information generally, are, without limitation, based on
the assumptions and subject to the risks set out herein. The company’s results of operations and estimated and
forecasted revenue may differ materially from management’s current expectations. Such information is presented
for illustrative purposes only and may not be an indication of the company’s actual future results of operations or
earnings.
Market and industry data contained in this presentation is based upon information, surveys or studies conducted by
independent third parties and independent industry or general publications and management’s knowledge of, and
experience in, the markets in which we operate or intend to operate. We have no reason to believe that such third-
party information is false or misleading in any material respect, however market and industry data is subject to
variation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data,
the voluntary nature of the data gathering process and other limitations and uncertainties inherent in any statistical
survey. This third-party information has not been independently verified by us or any of our respective directors,
officers or representatives and no representation is given as to the accuracy of any of the data from third party
sources referred to in this presentation.
The securities being offered pursuant to the subscription receipt offering are being offered on a private placement
basis in reliance upon prospectus and registration exemptions under applicable securities legislation. Resale of the
securities offered hereunder will be subject to restrictions under applicable securities legislation, which will vary
depending on the relevant jurisdiction. Generally, such securities may be resold only pursuant to an exemption from
the prospectus and registration requirements of applicable securities legislation or pursuant to an exemption order
granted by appropriate securities regulatory authorities.
The securities being offered pursuant to the subscription receipt offering have not, nor will they be, registered under
the United States Securities Act of 1933, as amended, or the securities laws of any state of the United States and may
not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of
U.S. registration or an applicable exemption from the U.S. registration requirements. This presentation does not
constitutes an offer for sale of securities in the United States.
FORWARD LOOKING STATEMENTS

3. page 3
INVESTMENT HIGHLIGHTS
• One of the largest providers of chronic pain services in
Canada
• 9 pain clinic locations across Canada
• 3-year revenue growth - $600k (2018) to $12.6 million
(2020) 1
• Largest medical cannabis telehealth network in Canada
• Leading partner with Canadian pharmacy companies for
medical cannabis
• MySpark TM proprietary IT – ‘actionable digital
intelligence’
• $13.8 million over subscribed financing (March 2021)
• Anticipated TSX.V trading – early-June/21 (PHC.V)
1. These are unaudited revenue figures. The revenue figures include management's best estimate of additional revenue in relation to the acquisition
of NHS, NACM Clinic and Pharmacy business and NMI as if it happened January 1, 2020.

4. LEADERSHIP TEAM
page 4
Wayne Cockburn
President
Aura Balboa
CFO
Ken Yoon
CEO
Over 25 years of healthcare experience, including
20 years at the C-level, specializing in strategic
planning, corporate finance and capital market
strategies, corporate partnering, corporate
governance and mergers and acquisitions. Mr.
Cockburn brings over 35 years of capital market
experience and has served on the board of
directors of U.S. and Canadian private and public
companies for more than 20 years.
Over 15 years of finance and operations
experience to PHC. Ms. Balboa began her career
in public accounting with Deloitte. She then held
a number of finance roles with increasing
responsibilities at multiple pharmaceutical
companies both in Canada and the US. Her most
recent role was Director of Finance at Acerus
Pharmaceuticals Corporation, a Canadian
pharmaceutical company listed on the TSX.
25 years of experience in consulting, financing,
investing and building innovative private and
public companies with over $500M in
transactions. Prior to PHC, Mr. Yoon was CFO at a
TSX listed pharmaceutical company and a private
nanotech company, an investment professional at
what was one of largest venture capital firms in
Canada, and held several positions at Ernst &
Young, notably as a co-founder of a multi-
disciplinary business advisory group. Mr. Yoon is a
CPA, CA, holds an MBA, Law Degree, and BSc.

5. page 5
Over 30 years of executive level leadership
experience in healthcare. Mr. Wei has a track
record for developing and delivering innovative
allopathic and complementary medicine models
in North America.
Mr. Wei is a co-founder of The Clinic Network
and has helped grow PHC to be a Canadian
delivery system with corporate and joint-venture
clinics, in multiple healthcare disciplines. Mr.
Wei has acted as a Director on multiple Canadian
and international company Boards.
Over 20 years of experience in the healthcare
industry in a variety of capacities and increasingly
senior roles, including sales, business
development, and operations. Prior to joining
PHC, Ms. John was VP of Operations for Agility
Health. For over a decade, she previously served
as Director, Western CDA Sales and Operations at
Shoppers Home Health Care, a division of
Shoppers Drug Mart, where she was responsible
for a diverse six figure portfolio. Ms. John holds
an Executive MBA from the Ivey School of
Business -University of Western Ontario.
Over 20 years of experience in various facets of
the healthcare sector. Mr. Sandhu is the former VP
of Medical Operations and Business Optimization
for National Access Cannabis Medical. Mr. Sandhu
is also an active clinical pharmacist, who has a
passion for developing innovative programs in
regulated environments. In 2014, he was a
recipient of the Trillium Health Partners Allied
Health Professional Award. Mr. Sandhu holds a
Professional Certificate in Cannabis Science and
Medicine from the University of Vermont’s Larner
College of Medicine.
Kim Wei
Chief Commercial Officer
Renee John
VP, Clinic Operations
Pram Sandhu
VP, Pharmacy Programs & Regulatory Affairs
LEADERSHIP TEAM

6. page 6
PREVALENT
1 in 5 Canadian adults
experience chronic pain 1
LACK OF SPECIALISTS
Specialized pain services
are largely inaccessible
BURDENSOME
>$50 billion in health
care resources and
productivity losses 2
UNDER CAPACITY
1-3 Years average wait time
for treatment at publicly-
funded pain clinics in
Canada 3
1 Schopflocher et al., 2011; Reitsma et al., 2011; Steingrimsdottir et al., 2017, Canadian Pain Task Force Report, June 2019
2 https://www.benefitscanada.com/benefits/health-benefits/chronic-pain-costs-employers-52439
3 http://www.canada.com/health/live+this+life+pain+Canadians+with+chronic+pain+struggling+find+help+hope/5485154/story.html
CHRONIC PAIN–A LARGE AND GROWING PROBLEM

7. The Opportunity
page 7
• Fragmented industry – opportunity for consolidator
• Accretive acquisitions - build on existing
infrastructure
• Pharmacy partnerships
• Cannabis 3.0 (2021/22) – focus on medical; opioid
harm reduction; public dialogue of alternative
approaches to pain management
• Partnering opportunities – Workers Comp, unions,
insurance companies, family medical practices, allied
health, LPs, First Nations, government, clinical trials
• Improve access for patients

8. page 8
BUSINESS UNITS
• Network of pain clinics in
major markets across
Canada
• Interdisciplinary
procedures by trained
pain specialists
• Largest medical cannabis
telehealth network in the
country
• Pharmacy partnerships
• MY SPARK TM
• Web-based platform
• Proprietary data
management system
• Referral portal for
doctors, allied health
clinicians, nurses,
pharmacists, patients
• Creating an online
community
• Slawner Ortho (Est. 1952)
• Leader in Montreal (and
surrounding areas) in
Orthotics, Prosthetics, and
Home Healthcare products
• Cannabis Health Products
for clinics and pharmacy
partners (in discussions)
• Co-branding
opportunities
Innovations
Products
Services

9. page 9
SERVICES GROWTH PLANS (2021/22)
• Current 9 locations include Toronto,
Montreal (3), Chateauguay, Magog,
Saskatoon, Winnipeg, Selkirk
• Goal of 12 – 15 clinics across Canada
• Established clinics targeted for BC,
AB and East Coast through acquisition
or affiliation
• Locations for pain/harm reduction
referrals
• Expansion of interventional pain model
into current locations – ketamine
infusions, image-guided therapies, etc.

10. page 10
SERVICES AND PRODUCTS
- GROWTH PLANS (2021)
• Acquisition of new patients
• Accretive to existing active base of >50,000
patients
• Pharmacy referrals for medical cannabis, chronic
pain and harm reduction
• Development of proprietary Cannabis Health
Products (CHPs)
• Exploring Medical Sales License Without
Possession (Health Canada) for B2B (pharmacies)
and B2C sales (clinics)
• Pharmacies – products, co-branding opportunities

11. PHARMACY INITIATIVES
page 11
1. PHARMACIST EDUCATION & CERTIFICATION
Canadian Council on Continuing Education in Pharmacy medical
cannabis education for pharmacists for provincial accreditation
(bilingual) - program owned by, and exclusive to PHC
2. PATIENT REFERRALS
Goal - to become preferred chronic pain telemedicine provider to
Canadian pharmacies
Education/marketing support to pharmacies; refine dosing; Circle of
Care
3. PRODUCT DEVELOPMENT & DISTRIBUTION
Secure retail pharmacy shelf space for future CBD OTC product
distribution

12. page 12
“Preparing pharmacy professionals to play an active, and appropriate,
role in the rapidly evolving world of cannabis”
• Cannabis 3.0 - bringing the benefits of cannabis derivatives (e.g. CBD) into mainstream health
products
• New consumer packaged goods category – pharmacies have limited or no experience with
the category
• PHC is an expert in subject matter – national, medical, credible partner for pharmacies
• Canada has approximately 42,500 licensed pharmacists working in more than 10,000 pharmacies 1
• PHC has signed agreements with several national pharmacy providers to-date
• Targeting >2,000 retail pharmacies covered by agreements by Q4/21
CANNABIS 3.0 AND PHARMACY PARTNERSHIPS
Pharmacy Connection August 30, 2018
1 Canadian Pharmacists Association, https://www.pharmacists.ca/pharmacy-in-
canada/pharmacists-in-canada/

13. page 13
EXPANSION OF PRODUCT DEVELOPMENT AND DISTRIBUTION
1 https://mjbizdaily.com/chart-week-profit-margins-infused-products-can-sky-high/
Distribution network includes PHC’s
>350,000 patient database and
national pharmacy partners
Co-branding opportunities with
pharmacy partners for
preferential shelf space
Exclusive rights to proprietary
delivery system for increased
absorption of active ingredients - for
use with pharmacy and LP partners
CBD-infused products generally
have gross margins higher than
pharmaceutical drugs, wine, beer,
liquor and cigarettes 1

14. PLPs 1
MY SPARKTM –ACTIONABLE DIGITAL INTELLIGENCE
page 14
Physicians
Pharmacies
MY
1. Preferred Licensed Producers
Patient
Portal

15. page 15
FINANCIAL OVERVIEW
LP Revenue Provincial Billing Non-Insured Billing Product Sales
31.4%
46.8%
17.8%
4%
2018
Revenue (C$MM) 2
$12.6
$6.6
$0.6
2020E
2019
$3.9
• Education and
marketing revenue
• 100% gross margins
$5.9
• Physician billings
• 20% gross margins1
$0.5
• Patient private pay
• 80% gross margins
$2.2
• Quebec orthopaedic sales
• 70% gross margins
1. Gross margins on Provincial Billings expected to increase as further integration of recent acquisitions occurs.
2. These are unaudited revenue figures. The revenue figures include management's best estimate of additional revenue in relation to the acquisition
of NHS, NACM Clinic and Pharmacy business and NMI as if it happened January 1, 2020.

16. page 16
INDUSTRY COMPARABLES
Akumin Inc.
Carebook Technologies Inc.
CloudMD Software and Services Inc.
Empower Clinics
Greenbrook TMS Inc.
Jack Nathan Health
MCI OneHealth
Medical Facilities Corp.
MindBeacon Holdings Inc.
Neupath Health Inc.
Skylight Health
ThinkResearch (TRC Holdings)
VitalHub Corp
WELL Health Technologies
1. High and low removed.
-
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
9.0
10.0
2020 2021 2020 2021
TEV/Rev PRICE/SALES
Median Mean Pathway Health

17. page 17
Percentage Shares
Investor Group Ownership Outstanding
Cura-Can Health Corp. 55.5% 51,638,711
Convertible notes 11.6% 10,864,108
CPC (Colson Capital) 3.1% 2,856,171
Canaccord sub receipts 29.6% 27,600,000
Shares to Agents 0.2% 150,000
GRAND TOTAL 100% 93,108,990
CAP STRUCTURE
113,497,218 fully diluted shares outstanding. No derivative securities
have an exercise price less than issue price of $0.50 per share

18. SUMMARY
page 18
• >10,000 patient visits in 2020
• TCN completed 5 acquisitions since January 2019 to become the nation’s largest
chronic pain telemedicine network. Growing database of more than 350,000
patients for product distribution and data analytics.
Largest out-of-
hospital chronic
pain clinic in
Canada
Proven execution
and strategic
growth
• Revenue has grown from $600K to almost $13 million in 3 years. 1
• Signed 6 agreements in 2020 with some of the nation’s largest retail pharmacies
 becoming the leading referral partner for pain products and services for
thousands of Canadian pharmacies.
• Developing a unique IT platform allowing the company to scale pharmacy
initiative and expand its telemedicine services to many physicians.
• Expertise and experience to grow the business to become the dominant out-of-
hospital pain management business in Canada.
Proven
management
1. These are unaudited revenue figures. The revenue figures include management's best estimate of additional revenue in relation to
the acquisition of NHS, NACM Clinic and Pharmacy business and NMI as if it happened January 1, 2020.

19. page 19
Wayne Cockburn,
President
(905) 505-0770
wayne.cockburn@pathwayhealth.ca
Investor Relations
Dave Burwell,
Vice President, The Howard Group
(403) 410-7907
dave@howardgroupinc.com
Contact Information